Strategy to Control SPREAD of HIV Drug Resistance

Study Objective

The purpose of the SPREAD-programme is gaining a better insight in the transmission of drug resistant HIV in Europe

Participation conditions

Newly diagnosed HIV-infected patients who have not yet been previously treated with antiretroviral medication, who are willing to donate a sample of blood within 6 (but preferably 3) months of diagnosis and who have a viral load of at least 1000 copies/ml are eligible to participate in the SPREAD-programme.
 

Centers in Europe. A multidisciplinary collaboration of clinicians, epidemiologists and virologists from academic centres and public health institutes have been set up in 32 European countries for this programme.